Liraglutide
GLP-1 receptor agonist (Saxenda, Victoza)
The first daily-dose GLP-1 receptor agonist to gain FDA approval (Victoza for T2D in 2010, Saxenda for weight management in 2014). Now superseded by weekly Semaglutide and Tirzepatide for most patients, but remains relevant for users who titrate slowly, need adjustable daily dosing, or have insurance preference. -8% bodyweight average vs Semaglutide's -15% at peak doses.
Quick reference
How Liraglutide works
Liraglutide is a 31-amino-acid GLP-1 analog with a fatty-acid side chain that extends serum half-life from native GLP-1's 2 minutes to ~13 hours. This is what enables once-daily dosing — a major advance when introduced in 2010 vs the previous twice-daily exenatide.
Mechanism is identical to Semaglutide: appetite suppression via central GLP-1 receptors, delayed gastric emptying, glucose-dependent insulin secretion, and improved insulin sensitivity. The shorter half-life means smaller plasma steady-state but also faster clearance — useful if adverse effects emerge.
Why Liraglutide is mostly historical: Semaglutide (2017) achieves greater weight loss with weekly dosing. Tirzepatide (2022) achieves substantially greater weight loss with weekly dosing. Liraglutide remains relevant for: insurance preference, daily-titration flexibility (some users tolerate daily ramping better than weekly steps), and pediatric / age-specific FDA indications where Liraglutide retains coverage gaps Semaglutide hasn't filled.
In the DoseCraft framework, Liraglutide targets Insulin Resistance (improved glycemic control) and Inflammation (GLP-1 receptor activity reduces inflammatory cytokines), but at lower magnitude than weekly alternatives.
Safety + side-effect profile
Side-effect profile mirrors Semaglutide and Tirzepatide. GI effects dominate during titration. The shorter half-life means side effects can clear within 24-48 hours of dose adjustment, vs Semaglutide's week-long persistence.
Documented serious risks: pancreatitis (rare, similar to other GLP-1s), gallbladder issues, MTC theoretical FDA boxed warning (contraindicated in MEN-2 / family history). Contraindications: type 1 diabetes, severe gastroparesis, active gallbladder disease, pregnancy, breastfeeding.
Critical interactions: never stack with Semaglutide, Tirzepatide, or Retatrutide — all are GLP-1 receptor agonists, no added efficacy, compounded GI burden. Caution with insulin and sulfonylureas (hypoglycemia risk).
Lean mass: same caveat as Semaglutide — without resistance training + 1.6-2.2 g protein per kg per day, ~30-40% of weight lost is lean mass.
- • Nausea (very common during titration; usually resolves)
- • Constipation or diarrhea (alternating common)
- • Reflux / GERD (especially with large meals)
- • Hypoglycemia in insulin-using diabetics (manage with insulin dose reduction)
- • Loss of food noise (intended effect)
Frequently asked
What is Liraglutide?
Liraglutide is a daily-dose GLP-1 receptor agonist FDA-approved as Victoza (T2D, 2010) and Saxenda (weight management, 2014). The first daily-dose GLP-1 to enable practical chronic use, now largely superseded by weekly Semaglutide for most patients.
Liraglutide vs Semaglutide — when to use which?
Semaglutide is generally preferred: greater weight-loss efficacy (-15% vs -8% at peak doses), once-weekly dosing, often better insurance coverage post-2021. Liraglutide remains relevant for: pediatric indications where Semaglutide isn't approved, daily-titration flexibility for users who can't tolerate weekly steps, insurance-driven preference.
What is the standard Liraglutide titration?
Saxenda (weight loss) protocol: 0.6 mg daily × 1 week → 1.2 mg × 1 week → 1.8 mg × 1 week → 2.4 mg × 1 week → 3.0 mg maintenance. Victoza (T2D) protocol: 0.6 mg × 1 week → 1.2 mg → optionally 1.8 mg. Weekly increments allow faster ramping than Semaglutide's monthly steps.
Can I switch from Liraglutide to Semaglutide?
Yes. Standard transition: stop Liraglutide → wait 2-3 days (13-hour half-life clears) → start Semaglutide at 0.25 mg weekly. Don't stack the two. Most users tolerate the switch well; some experience mild nausea recurrence in the first 2 weeks of Semaglutide.
Does Liraglutide cause less weight loss than Semaglutide?
Yes. Saxenda peak weight loss: ~8% bodyweight at 56 weeks (3 mg daily). Wegovy (Semaglutide) peak weight loss: ~14.9% at 68 weeks (2.4 mg weekly). The difference reflects both weekly-vs-daily plasma stability and dose magnitude. Tirzepatide reaches ~22.5%.
Is daily Liraglutide harder to stick with than weekly Semaglutide?
Compliance studies show meaningfully higher long-term adherence with weekly Semaglutide vs daily Liraglutide. The daily injection is the dominant practical drawback. Some users prefer daily titration for adverse-effect management — if nausea peaks, you've cleared the dose within 24 hours rather than persisting through a 5-day half-life.
Are there long-term safety concerns?
15+ years of cumulative safety data from Victoza. Documented risks: pancreatitis (rare, <1%), gallbladder issues, MTC theoretical FDA caution. Cardiovascular safety is favorable (LEADER trial: -13% major adverse cardiovascular events vs placebo). Long-term safety profile is well-characterized.
Related compounds
Often researched, stacked, or compared with Liraglutide.
Build your Liraglutide protocol with Coach
Coach personalizes the dose, stack, and cycle for your specific goals — and saves the result as a cited PDF you can bring to your doctor. Free for 14 days.
Start 14-Day Free TrialNo credit card · cancel anytime